Diagnosis and management of mood disorders during the menopausal transition.
Recent census data indicate that, in the United States, an increasing number of women--almost 1.5 million each year--are reaching menopause. The menopausal transition is marked by intense hormonal fluctuations, and may be accompanied by vasomotor complaints, sleep disturbances, changes in sexual function, and increased risk for osteoporosis and cardiovascular disease. In addition, there is evidence of increased risk for developing depression, even among women who never experienced depressive symptoms before. Thus depression during the perimenopause may have a substantial impact on personal, family, and professional spheres of life. A challenge to clinicians and health professionals lies in the identification of the most tolerable treatments to manage depression and improve quality of life in an aging population. Any treatment strategy should take into account not only the spectrum of side effects that may complicate treatment but also other menopause-related factors (e.g., vasomotor symptoms, psychosocial stressors) that may modulate risk for the development of mood disturbance. This article reviews the current literature on the prevalence and risk factors associated with depression during the menopausal transition. The benefits and risks of using hormonal and nonhormonal strategies for the management of depression and other menopause-related somatic symptoms are critically reviewed.
Cohen
Lee S
LS
Department of Perinatal and Reproductive Psychiatry, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts 02114, USA. lcohen2@partners.org
Soares
Claudio N
CN
Joffe
Hadine
H
D000928:Antidepressive Agents / Q000627:therapeutic use; D015914:Estrogen Replacement Therapy; D005260:Female; D019584:Hot Flashes; D006801:Humans; D008593:Menopause / Q000502:physiology / Q000523:psychology*; D019964:Mood Disorders / Q000175:diagnosis / Q000209:etiology* / Q000628:therapy; D018570:Risk Assessment
D000928:Antidepressive Agents